首页> 美国卫生研究院文献>BMC Biochemistry >The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand
【2h】

The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand

机译:肝素辅因子II的N末端完整延伸是凝血酶外位1配体发挥最大功效所必需的

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundHeparin cofactor II (HCII) is a circulating protease inhibitor, one which contains an N-terminal acidic extension (HCII 1-75) unique within the serpin superfamily. Deletion of HCII 1-75 greatly reduces the ability of glycosaminoglycans (GAGs) to accelerate the inhibition of thrombin, and abrogates HCII binding to thrombin exosite 1. While a minor portion of HCII 1-75 can be visualized in a crystallized HCII-thrombin S195A complex, the role of the rest of the extension is not well understood and the affinity of the HCII 1-75 interaction has not been quantitatively characterized. To address these issues, we expressed HCII 1-75 as a small, N-terminally hexahistidine-tagged polypeptide in E. coli.
机译:背景肝素辅因子II(HCII)是一种循环蛋白酶抑制剂,其在丝氨酸蛋白酶抑制剂(Serpin)超家族中含有独特的N末端酸性延伸(HCII 1-75)。删除HCII 1-75会大大降低糖胺聚糖(GAG)加速凝血酶抑制的能力,并废除HCII与凝血酶异位点1的结合。而在结晶的HCII-凝血酶S195A中可以看到HCII 1-75的一小部分。复杂的,其余扩展的作用尚不十分了解,HCII 1-75相互作用的亲和力尚未得到定量表征。为了解决这些问题,我们在大肠杆菌中将HCII 1-75表达为N-末端带有六组氨酸标签的小多肽。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号